#United States #New York #Citius Pharmaceuticals #LYMPHIR #Citius Oncology

Citius Pharmaceuticals and Citius Oncology: Upcoming Investor Conferences in October 2025

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), are gearing up for a significant presence at three major investor events scheduled in October 2025. With a focus on sharing insights into their innovative biopharmaceutical products and their ongoing development strategies, these conferences provide a platform for the companies to strengthen connections with investors.

Conference Schedule

1. LD Micro Main Event XIX
- Dates: October 19-21, 2025
- Location: Hotel Del Coronado, San Diego, California
- Event Website for Registration

2. Maxim Growth Summit 2025
- Dates: October 22-23, 2025
- Location: Hard Rock Hotel, New York
- Event Website for Registration

3. Think Equity Conference
- Dates: October 30, 2025
- Location: Mandarin Oriental, New York
- Event Website for Registration

Participants interested in one-on-one meetings with management from Citius Pharmaceuticals can register via the event platforms or reach out to the company's investor relations team for scheduling.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is dedicated to developing and commercializing first-in-class critical care products. Among its notable achievements, the company secured FDA approval for LYMPHIR, a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma, in August 2024. This breakthrough positions them well within a market projected to exceed $400 million, catering to patients who require innovative therapies after failing previous treatments.

Furthermore, Citius’s late-stage pipeline includes additional promising products such as Mino-Lok®, designed to salvage catheters in patients vulnerable to bloodstream infections, and CITI-002 (Halo-Lido), a topical solution aimed at providing relief from hemorrhoids.

In 2023, the Phase 3 trial results for Mino-Lok indicated efficacy in meeting both primary and secondary endpoints, prompting active discussions with the FDA regarding the next steps for its progression.

About Citius Oncology, Inc.

Citius Oncology specializes in the development and commercialization of novel targeted therapies for oncology. The company’s flagship product, LYMPHIR, was also approved by the FDA in August 2024, addressing the needs of adults suffering from relapsed or refractory cutaneous T-cell lymphoma after their initial treatment. The company emphasizes the importance of robust intellectual property surrounding its products, which includes orphan drug designations and pending patents that will enhance its competitive edge in the oncology market.

Citius Oncology, while a publicly traded subsidiary of Citius Pharmaceuticals, is carving its niche in the evolving landscape of cancer therapies, further ensuring that they meet the demands of an expanding, underserved market.

With these conferences on the horizon, Citius Pharmaceuticals and Citius Oncology not only aim to boost investor relations but also to communicate their commitment to innovation in the biopharmaceutical sector. Their emphasis on critical care products highlights an acute awareness of the healthcare challenges and an unwavering dedication to finding solutions.

For more information about their participation in these conferences and updates on their product lines, visit Citius Pharmaceuticals and Citius Oncology.